3,4-DAA exhibits potent anti-inflammatory activity and can alleviate colitis symptoms by inhibiting Th1 cell responses, promoting Th2 cytokine expression, and inducing CD4+CD25+ T cell expression; it also suppresses the expression of inducible nitric oxide synthase (iNOS) and the release of nitric oxide (NO) in EOC20 cells induced by IFN-γ and lipopolysaccharide.